A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: Clinical efficacy and side effects

1993 ◽  
Vol 91 (3) ◽  
pp. 709-722 ◽  
Author(s):  
L HAUGAARD ◽  
R DAHL ◽  
L JACOBSEN
Keyword(s):  
Side Effects ◽  
Clinical Efficacy ◽  
Dose Response ◽  
House Dust ◽  
House Dust Mite ◽  
Dust Mite ◽  
Dose Response Study

Clinical Efficacy Of Subcutaneous and Sublingual Immunotherapy In Asthma and Rhinitis Children Sensitized To House Dust Mite

2014 ◽  
Vol 133 (2) ◽  
pp. AB146
Author(s):  
Min-Ju Kim ◽  
Eun Lee ◽  
Keun-Mi Park ◽  
Keum-Hee Hwang ◽  
Young-Ho Jung ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
House Dust ◽  
House Dust Mite ◽  
Sublingual Immunotherapy ◽  
Dust Mite

scholarly journals Tinnitus after administration of sublingual immunotherapy

2017 ◽  
Vol 5 ◽  
pp. 2050313X1771315
Author(s):  
Jacob Juel
Keyword(s):  
Allergic Rhinitis ◽  
Abdominal Pain ◽  
Clinical Practice ◽  
Side Effects ◽  
Respiratory Tract ◽  
House Dust ◽  
House Dust Mite ◽  
Clinical Case ◽  
Sublingual Immunotherapy ◽  
Dust Mite

Background/objectives: Sublingual immunotherapy was first described in 1986. Since then, its use has been increased as an alternative to subcutaneously administered immunotherapy in the treatment of allergic rhinitis. The most common side effects are of oropharyngeal and gastrointestinal in nature, for example, itching, swelling, irritation, ulceration of the oropharynx and nausea, abdominal pain, diarrhoea, and vomiting. More severe side effects are dominated by systemic and respiratory tract manifestations. Results: In this clinical case, the author reports a right-sided transient tinnitus lasting for 48 h after administration of sublingual immunotherapy for house dust mite in allergic rhinitis. Conclusions: This case provide important insights for clinical practice, as tinnitus has not been previously reported as a side effect of sublingual immunotherapy with house dust mite allergens.

scholarly journals Safety of house dust mite subcutaneous immunotherapy in preschool children with respiratory allergic diseases

2021 ◽  
Vol 47 (1) ◽  
Author(s):  
Yaqi Yang ◽  
Dongxia Ma ◽  
Nan Huang ◽  
Wenjing Li ◽  
Qing Jiang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Preschool Children ◽  
Side Effects ◽  
House Dust ◽  
House Dust Mite ◽  
Allergic Diseases ◽  
Subcutaneous Immunotherapy ◽  
Multivariable Logistic Regression Analysis ◽  
Causal Therapy ◽  
Dust Mite

Abstract Background Allergen immunotherapy (AIT) is the only causal therapy for IgE-mediated allergy. There is less evidence about the safety and efficacy of AIT especially subcutaneous immunotherapy (SCIT) in children under 5 years old. We aimed to investigate the side effects and associated risk factors of house dust mite (HDM) SCIT in preschool children with respiratory allergic diseases. Methods The preschool children who had HDM-related allergic rhinitis with/without asthma were enrolled and undergone standardized HDM SCIT in our department from June 2013 to December 2019. Local reactions (LRs) and systemic reactions (SRs) were recorded and categorized according to World Allergy Organization recommendations. Demographic data and other therapeutic-related parameters were also recorded to investigate potential risk factors for these side effects. Results A total of 91 children (60 boys, 65.93%; 31 girls, 34.07%; mean age 4.13 years old) were included in the study. Among the 91 patients, 3109 SCIT injections were recorded, 62/91 (68.13%) experienced 186 immediate LRs, 4 /91(4.40%) experienced 6 delayed LRs, 11/91 (12.09%) children experienced 44 immediate SRs, 21/44 (47.73%) were grade 1 SRs, 21/44 (47.73%) were grade 2, 2/44 (4.55%) were grade 3, no grade 4 or 5 SRs occurred. Furthermore, 1/91 (1.10%) experienced 1 delayed SRs, manifested by urticaria 2 days later after allergen injection. 9/91 (9.89%) experienced 2 or more times SRs. Multivariable logistic regression analysis showed BMI (OR 1.506; 95%CI 1.091 to 2.079; p < 0.05) and sIgE against HDM (OR 1.497; 95%CI 1.082 to 2.071; p < 0.05) were risk factors for LRs. No variable was found to correlate with SRs (all p > 0.05). Conclusions HDM subcutaneous immunotherapy is considered to be safe in preschool children with respiratory allergic diseases. Higher BMI and HDM sIgE level in children are risk factors for developing LRs. The incidence of SRs and the rate of severe SRs are low in preschool children.

scholarly journals Clinical Efficacy of House Dust Mite-specific Immunotherapy in Asthmatic Children

2010 ◽  
Vol 51 (1) ◽  
pp. 14-18 ◽  
Author(s):  
Tzu-Chun Tsai ◽  
Jen-Her Lu ◽  
Shu-Jen Chen ◽  
Ren-Bin Tang
Keyword(s):  
Clinical Efficacy ◽  
House Dust ◽  
House Dust Mite ◽  
Specific Immunotherapy ◽  
Asthmatic Children ◽  
Dust Mite

Clinical Efficacy and Possible Mechanism of Endoscopic Vidian Neurectomy for House Dust Mite-Sensitive Allergic Rhinitis

ORL ◽  
2021 ◽  
pp. 1-10
Author(s):  
Li Shen ◽  
Jun Wang ◽  
Xue Kang ◽  
Mei Han ◽  
Mengyue Li ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Clinical Efficacy ◽  
House Dust ◽  
House Dust Mite ◽  
Immunoglobulin E ◽  
Serum Levels ◽  
Vidian Neurectomy ◽  
Tnf Α ◽  
Dust Mite

<b><i>Background/Aims:</i></b> Endoscopic vidian neurectomy (EVN) for allergic rhinitis (AR) has good clinical effects. However, the pathophysiological basis of the effect of EVN on AR is still poorly understood. This study aimed to investigate the efficacy of EVN on house dust mite (HDM)-sensitive AR and the dynamic changes of serum immunoglobulin E and some immune regulatory factors. <b><i>Methods:</i></b> Twenty HDM-sensitive AR patients were treated with bilateral EVN (EVN group), 15 HDM-sensitive AR patients were treated with subcutaneous immunotherapy (SCIT group), and 15 healthy subjects served as healthy controls. Quality of daily life was assessed by the scores of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQs). The visual analog scale was used to assess clinical efficacy. Serum molecules were measured by ELISA and the UNICAP system. <b><i>Results:</i></b> Compared with the SCIT group, the RQLQs in the EVN group were lower 12 months after treatment (both <i>p</i> &#x3c; 0.05). There was no significant difference in improving nasal itching and sneezing (both <i>p</i> &#x3e; 0.05), but the clinical efficacy of bilateral EVN was greater than SCIT in improving nasal obstruction, rhinorrhea, eye itching, and lachrymation 12 months after treatment (all <i>p</i> &#x3c; 0.05). Compared with before treatment, the serum levels of total immunoglobulin E (tIgE), <i>Dermatophagoides pteronyssinus</i>- and <i>Dermatophagoides farinae</i>-specific immunoglobulin E (sIgE), and tumor necrosis factor (TNF)-α in the EVN group and the serum levels of TNF-α and interleukin-4 in the SCIT group were lower 12 months after treatment (all <i>p</i> &#x3c; 0.05). <b><i>Conclusion:</i></b> The short-term efficacy of bilateral EVN is more effective than SCIT in treating HDM-sensitive AR. This may be because the surgery reduced the tIgE and sIgE levels. TNF-α may be involved in the therapeutic mechanism.

Sign in / Sign up

Export Citation Format

Share Document